In a 59-year-old woman with diabetes who is experiencing increased confusion while taking guanfacine, alprazolam (Xanax), amitriptyline, fluoxetine (Prozac), and lamotrigine (Lamictal), which agents should be tapered first and how should the medication reduction be safely prioritized?

Medication Deprescribing Strategy for Confusion in a Diabetic Patient on Polypharmacy

Immediate Priority: Discontinue Alprazolam (Xanax) First

Alprazolam should be tapered and discontinued as the first priority, as benzodiazepines are a leading cause of confusion in older adults and carry significant risks of cognitive impairment, falls, and paradoxical reactions including confusion. 1

Rationale for Alprazolam Discontinuation

• Benzodiazepines directly cause confusion and cognitive impairment, particularly in patients over 50 years old, with alprazolam specifically causing confusional states in 10.4% of panic disorder patients and memory impairment in 33.1% 1
• The FDA label explicitly warns that alprazolam causes sedation, drowsiness, cognitive disorder (28.8%), memory impairment (33.1%), and confusional state (10.4%) in clinical trials 1
• Drug interactions are critical here: alprazolam combined with fluoxetine results in a 30% increase in plasma alprazolam concentrations and increased psychomotor decrements compared to alprazolam alone 2
• Consensus guidelines recommend against sedative medications (benzodiazepines) in sick day guidance, though this achieved only 47% consensus, suggesting significant concern about their use in vulnerable patients 3

Alprazolam Tapering Protocol

• Reduce by no more than 0.5 mg every 3 days to prevent withdrawal seizures 1
• Some patients may require an even slower taper; monitor for withdrawal symptoms including anxiety, insomnia, and irritability 1
• Do not abruptly discontinue due to risk of withdrawal seizures 1

---

Second Priority: Discontinue or Reduce Amitriptyline

Amitriptyline should be tapered next, as tricyclic antidepressants worsen glucose control in diabetic patients and cause significant anticholinergic side effects including confusion, particularly in older adults.

Rationale for Amitriptyline Discontinuation

• Amitriptyline worsens glycemic control in diabetic patients: nortriptyline (a similar norepinephrine reuptake inhibitor) led to worsening indices of glucose control in patients with comorbid diabetes and depression 4
• Tricyclic antidepressants increase cravings and increase fasting blood glucose levels 4
• Anticholinergic effects are pronounced and contribute to confusion, particularly in combination with other CNS-active medications 5
• While amitriptyline showed 74% moderate or greater pain relief in diabetic neuropathy, desipramine (61%) and fluoxetine (48%) also provided benefit 5
• In a direct comparison, amitriptyline caused 75% of adverse events (33 of 44 total), with sedation being the most common in 43% of patients, compared to only 25% adverse events with lamotrigine 6

Amitriptyline Tapering Considerations

• The patient is already on fluoxetine (Prozac), which provides antidepressant coverage and has been shown to improve glucose control in diabetic patients 4
• If amitriptyline was prescribed for diabetic neuropathy pain, lamotrigine 25 mg twice daily is a safer alternative with fewer adverse effects and no worsening of glucose control 6
• Taper gradually over 2-4 weeks to avoid discontinuation symptoms

---

Third Priority: Evaluate Guanfacine

Guanfacine should be carefully evaluated and potentially reduced or discontinued, as it causes sedation and has additive CNS depressant effects with the other medications this patient is taking.

Rationale for Guanfacine Evaluation

• Guanfacine causes dose-related sedation and drowsiness, especially when beginning therapy 7
• The FDA label explicitly warns: "When guanfacine is used with other centrally active depressants (such as phenothiazines, barbiturates, or benzodiazepines), the potential for additive sedative effects should be considered" 7
• This patient is taking multiple CNS depressants (alprazolam, amitriptyline), creating significant additive sedation risk 7
• Patients should be warned that their tolerance for alcohol and other CNS depressants may be diminished 7

Guanfacine Management

• If guanfacine is being used for ADHD in this 59-year-old (off-label use), reconsider the risk-benefit ratio given the polypharmacy and confusion
• If continued, ensure it is not being combined with other CNS depressants after alprazolam and amitriptyline are discontinued
• Do not discontinue abruptly due to risk of rebound hypertension; taper gradually if discontinuing 7

---

Medications to Continue

Fluoxetine (Prozac): Continue

• Fluoxetine improves glucose control in diabetic patients: studies at 60 mg/day for up to 12 months demonstrated reductions in weight (up to 9.3 kg), fasting plasma glucose (up to 45 mg/dL), and HbA1c (up to 2.5%) 4
• Fluoxetine and sertraline (both SSRIs) produced results consistent with reductions in glucose levels in patients with comorbid diabetes and depression 4
• Most evidence supports the use of fluoxetine in control of glucose handling in comorbid diabetes and depression 4
• Fluoxetine does not cause the cognitive impairment or confusion seen with tricyclics or benzodiazepines 5

Lamotrigine (Lamictal): Continue

• Lamotrigine is metabolically favorable and does not worsen glucose control 6
• If being used for mood stabilization, it has demonstrated efficacy in augmentation with fluoxetine for resistant depression 8
• If being used for diabetic neuropathy pain, lamotrigine 25 mg twice daily is associated with fewer adverse effects than amitriptyline (25% vs 75% adverse event rate) 6
• Lamotrigine does not cause sedation or confusion at therapeutic doses 6

---

Diabetes-Specific Medication Considerations

Sick Day Medication Guidance Relevance

• While this patient's confusion is not due to acute illness, the consensus guidelines identify "reduced level of consciousness or new confusion" as a severe symptom requiring contact with healthcare provider 3
• This underscores the urgency of addressing medication-induced confusion in diabetic patients 3

Metabolic Monitoring

• Ensure the patient is not on any antipsychotic medications (not mentioned in the medication list), as second-generation antipsychotics require screening for prediabetes or diabetes at baseline, 12-16 weeks, and annually 9, 10
• Monitor HbA1c and fasting glucose after medication changes, particularly after discontinuing amitriptyline and continuing fluoxetine 4

---

Stepwise Deprescribing Algorithm

1. Week 1-2: Begin alprazolam taper (reduce by 0.5 mg every 3 days) 1
2. Week 3-4: Once alprazolam is discontinued, begin amitriptyline taper (reduce by 25 mg every week)
3. Week 5-6: Reassess confusion status after both medications are discontinued
4. Week 7-8: If confusion persists, evaluate guanfacine dose reduction or discontinuation 7
5. Throughout: Continue fluoxetine and lamotrigine, as both are metabolically favorable and do not cause confusion 4, 6

---

Common Pitfalls to Avoid

• Do not discontinue alprazolam abruptly due to seizure risk 1
• Do not assume the confusion will resolve immediately; benzodiazepine effects can persist for weeks after discontinuation
• Do not discontinue all medications simultaneously; sequential tapering allows identification of the causative agent
• Do not overlook the fluoxetine-alprazolam interaction, which increases alprazolam levels by 30% and worsens psychomotor performance 2
• Do not continue amitriptyline for diabetic neuropathy when safer alternatives (lamotrigine) are available and the patient is already experiencing confusion 6
• Monitor for worsening depression or anxiety during benzodiazepine and tricyclic discontinuation, though fluoxetine should provide adequate antidepressant coverage 4